2.30
Oramed Pharmaceuticals Inc stock is traded at $2.30, with a volume of 83,145.
It is up +7.98% in the last 24 hours and up +9.00% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$2.13
Open:
$2.2495
24h Volume:
83,145
Relative Volume:
1.26
Market Cap:
$93.94M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
20.91
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
+9.00%
1M Performance:
+9.00%
6M Performance:
+0.00%
1Y Performance:
-12.55%
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ORMP
Oramed Pharmaceuticals Inc
|
2.30 | 87.00M | 2.70M | 5.53M | -10.55M | 0.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
Apr-20-21 | Initiated | Canaccord Genuity | Buy |
Feb-09-21 | Initiated | National Securities | Buy |
Dec-03-20 | Initiated | Alliance Global Partners | Buy |
Mar-11-20 | Initiated | Aegis Capital | Buy |
Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
May-26-16 | Reiterated | FBR Capital | Outperform |
Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
Nov-19-15 | Initiated | FBR Capital | Outperform |
Apr-13-15 | Resumed | MLV & Co | Buy |
Jan-30-14 | Reiterated | Aegis Capital | Buy |
Jan-08-14 | Reiterated | Aegis Capital | Buy |
Jan-08-14 | Initiated | MLV & Co | Buy |
Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
What analysts say about Oramed Pharmaceuticals Inc. stockFree Popular Stock Recommendations - Autocar Professional
Oramed Pharmaceuticals Inc. Stock Analysis and ForecastSky-high return potential - Autocar Professional
Oramed Pharm and Scilex Finalize Option Agreement - TipRanks
Oramed Pharmaceuticals enters option agreement with Scilex for warrant repurchase - MarketScreener
Is Oramed Pharmaceuticals Inc. a good long term investmentAccelerated capital growth - jammulinksnews.com
What drives Oramed Pharmaceuticals Inc. stock priceExceptional financial outcomes - jammulinksnews.com
Oral Proteins & Peptides Market to Surge to US$24 Billion by 2030, Driven by Chronic Disease Burden and Drug Delivery Innovation - Barchart.com
What makes Oramed Pharmaceuticals Inc. stock price move sharplyFree Group Entry - Newser
Why Oramed Pharmaceuticals Inc. stock attracts strong analyst attentionRisk Managed Trading Strategy - Newser
How Oramed Pharmaceuticals Inc. stock performs during market volatilityFree Investment Community - Newser
Head to Head Survey: Oramed Pharmaceuticals (NASDAQ:ORMP) and Smith & Nephew SNATS (NYSE:SNN) - Defense World
Alpha Tau Medical's $36.9M Financing: A Strategic Leap Toward Revolutionary Cancer Therapy - AInvest
Oramed Pharmaceuticals : Announces Xiaoming Gao Joins Board of Directors - marketscreener.com
Oral Biologics Market Outlook 2025: Rising Demand, Market Size, - openPR.com
Two Sigma Advisers LP Invests $662,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Oral Biologics Market in 2025-2032 Detailed Study Analysis with - openPR.com
Alpha Tau to Present at Jefferies Global Healthcare Conference - Stock Titan
Acusphere (OTCMKTS:ACUS) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving Average – Should You Sell? - Defense World
Oramed Pharm Extends Stock Buyback Program - TipRanks
Dimensional Fund Advisors LP Grows Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - Defense World
Oramed: Q1 Earnings Snapshot - New Haven Register
Alpha Tau Medical appoints new board member By Investing.com - Investing.com India
Alpha Tau Medical appoints new board member - Investing.com
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors - GlobeNewswire
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):